Brief: Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data Of Its Investigational Xerisol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (Xp-8121)

Xeris Biopharma Holdings

30/05/2024 13:27

May 30 (Reuters) - Xeris Biopharma Holdings Inc
 XERS.O :
    * XERIS BIOPHARMA ANNOUNCES POSITIVE TOPLINE PHASE 2
CLINICAL DATA
OF ITS INVESTIGATIONAL XERISOL™-FORMULATED ONCE-WEEKLY
SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121)
    * XERIS BIOPHARMA HOLDINGS INC - FDA END-OF-PHASE 2
INTERACTION TO
FACILITATE A PHASE 3 PIVOTAL STUDY PROGRAM IS EXPECTED BY
YEAR-END
    * XERIS BIOPHARMA HOLDINGS INC: FDA END-OF-PHASE 2
INTERACTION TO
FACILITATE A PHASE 3 PIVOTAL STUDY PROGRAM IS EXPECTED BY
YEAR-END
    * XERIS BIOPHARMA- XERISOL FORMULATION ENABLED PREDICTABLE
BIOAVAILABILITY & SUSTAINED LEVELS OF LEVOTHYROXINE IN
ONCE-WEEKLY SUBCUTANEOUS PRESENTATION

Source text for Eikon:  ID:nBw1MzmDqa 
Further company coverage:  XERS.O 

 ((Reuters.Briefs@thomsonreuters.com;))